Internal medicine

Inoculation

Tocilizumab

Disease

Immunology

Interstitial lung disease

Lung

Scleroderma (fungus)

Medicine

Arthritis & Rheumatology

Tocilizumab (TCZ) has demonstrated lung function preservation in 2 randomized controlled trials in early systemic sclerosis (SSc). This effect has yet to be characterized in terms of radiographically evident quantitative lung involvement. We undertook this study to assess the impact of TCZ on lung function preservation in a post hoc analysis, stratifying treatment arms according to the degree of lung involvement.

Tocilizumab Prevents Progression of Early Systemic Sclerosis–Associated Interstitial Lung Disease